TPST Antibody

Basic Research Questions

How do TPST antibodies enable detection of protein sulfation patterns in cancer biology?

TPST antibodies are critical for identifying tyrosine sulfation patterns through immunohistochemistry (IHC) and Western blotting. For example:

• IHC protocol: Semi-quantitative scoring of cytoplasmic staining intensity (0–3) and positive cell percentage (0–4) is used to calculate a composite score (≤1 = negative; ≥6 = strongly positive) .

• Validation: Include positive controls (normal lung tissue) and compare staining patterns across tumor subtypes (e.g., squamous carcinoma vs. adenocarcinoma) to confirm antibody specificity .

What methodologies ensure accurate quantification of TPST-1 expression in human tissues?

A standardized scoring system combining staining intensity and cellular distribution is recommended (see Table 1).

Example: In lung cancer, TPST-1 expression was detected in 60% of tumors vs. 100% of normal tissues, with scores ≤3 correlating with advanced TNM stages .

How do TPST isoforms (TPST-1 vs. TPST-2) differ in substrate specificity?

• TPST-1: Primarily sulfates secretory proteins (e.g., chemokines) and is linked to metastasis suppression .

• TPST-2: Preferentially modifies membrane-bound receptors (e.g., GPCRs) and shows distinct tissue distribution .
  Method: Use isoform-specific antibodies validated via knockouts or siRNA silencing.

What controls are essential for validating TPST antibody specificity in IHC?

• Negative: Tissue sections pre-treated with nonimmune serum.

• Positive: Normal lung tissue (TPST-1) or liver tissue (TPST-2) .

• Technical: Include a reference cell line with known TPST expression levels.

Advanced Research Questions

How to reconcile contradictory findings on TPST-1’s role in cancer progression?

Case Example: While TPST-1 downregulation correlates with lymph node metastasis in lung cancer , other studies report context-dependent pro-tumor effects.

• Resolution Strategy:

  • Stratify analysis by molecular subtypes (e.g., EGFR mutation status).

  • Perform multi-omics integration (RNA-seq + phosphoproteomics) to identify compensatory pathways.

  • Validate findings in syngeneic models with TPST-1 knockout .

What experimental designs elucidate TPST-1’s mechanistic link to c-Met signaling?

• Approach:

  • Co-immunoprecipitation (Co-IP) to test physical interaction between TPST-1 and c-Met.

  • Functional assays: Compare c-Met phosphorylation levels in TPST-1 knockdown vs. wild-type cells .

• Key Finding: TPST-1 expression inversely correlates with c-Met (ρ = -0.42, p < 0.05) in lung cancer .

How can TPST antibodies enhance therapeutic targeting of prostaglandin pathways?

• Preclinical Insight: Dual EP2/EP4 antagonists (e.g., TPST-1495) synergize with anti-PD-1 therapies by modulating PGE2 signaling .

• Method: Use TPST-1 antibodies to map sulfation sites on EP4 receptors and assess blockade efficacy via flow cytometry .

What are the challenges in translating TPST biomarker findings into clinical trials?

• Limitations:

  • Small sample sizes (e.g., n = 50 in lung cancer study ).

  • Lack of survival correlation data.

• Solution:

  • Collaborative meta-analyses across cancer types.

  • Develop multiplex IHC panels (TPST-1 + PD-L1 + c-Met) to stratify patients for trials .

Methodological Recommendations

• For Contradictory Data: Apply Bayesian meta-analysis to weight studies by sample size and methodology rigor .

• Multi-omics Integration: Pair TPST IHC data with RNA-seq to identify co-regulated pathways (e.g., angiogenesis, fatty acid oxidation) .